Warning: Declaration of tie_mega_menu_walker::start_el(&$output, $item, $depth, $args, $id = 0) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = Array, $id = 0) in /home5/artechne/public_html/hdom/wp-content/themes/sahifa/functions/theme-functions.php on line 1965
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease | hdom.org

Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease

‘The Pride-HD Phase 2 preliminary results are encouraging as they show – for the firts time – benefits on the disease progression, although the study did not meet its primary endpoint.’ said Prof. Ferdinando Squitieri – LIRH Foundation Scientific Director and Head of The Huntington Disease Research Unit at Casa Sollievo della Sofferenza Research Hospital, Italy – in the meeting with the HD families of the Oman HD Association held on the last October 3, 2016.

Read more on:
http://www.lirh.it/it/tutte-le-novit%C3%A0-dallehdn-meeting-2016-con-un-approfondimento-su-pridopidina

Official press release of Teva on:
http://www.tevapharm.com/news/teva_announces_results_from_exploratory_52_week_phase_2_pride_hd_study_of_pridopidine_in_huntington_disease_09_16.aspx